ANDA 90943, held by Rising. Capecitabine.
As of Nov 16, 2026, ANDA 90943 (Capecitabine), held by Rising, was first approved by FDA on Aug 8, 2014, with 7 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 8, 2014 | Original application | Approved | None posted |
| Capecitabine150MG · tablet;oral | Capecitabine | Rx |
| Capecitabine500MG · tablet;oral | Capecitabine | Rx |
| Sep 25, 2026 | Supplement 16Labeling · Standard review | Approved | None posted |
| Oct 10, 2024 | Supplement 15Labeling · Standard review | Approved | None posted |
| Sep 23, 2022 | Supplement 13Labeling · Standard review | Approved | None posted |
| Dec 17, 2019 | Supplement 5Labeling · Standard review | Approved | None posted |
| Dec 17, 2019 | Supplement 7Labeling · Standard review | Approved | None posted |
| Dec 17, 2019 | Supplement 12Labeling · Standard review | Approved | None posted |
| Feb 18, 2016 | Supplement 3Labeling · Standard review | Approved | None posted |
| Aug 8, 2014 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters